Brokerages Set Kymera Therapeutics, Inc. (NASDAQ:KYMR) Target Price at $131.62

by · The Markets Daily

Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report) have earned an average recommendation of “Moderate Buy” from the twenty-five ratings firms that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, twenty-one have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among brokers that have covered the stock in the last year is $131.6250.

Several equities analysts have recently commented on the company. TD Cowen upgraded Kymera Therapeutics to a “strong-buy” rating in a research note on Monday, August 24th. Barclays upped their price target on shares of Kymera Therapeutics from $133.00 to $139.00 and gave the company an “overweight” rating in a report on Thursday, August 6th. BTIG Research reiterated a “buy” rating and set a $134.00 price objective on shares of Kymera Therapeutics in a research note on Thursday, June 25th. Truist Financial raised their price objective on shares of Kymera Therapeutics from $116.00 to $136.00 and gave the stock a “buy” rating in a report on Monday, June 29th. Finally, Brookline Capital Markets restated a “buy” rating on shares of Kymera Therapeutics in a research note on Monday, June 8th.

Check Out Our Latest Analysis on KYMR

Insider Transactions at Kymera Therapeutics

In other Kymera Therapeutics news, CFO Bruce Jacobs sold 77,109 shares of the company’s stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $114.96, for a total transaction of $8,864,450.64. Following the sale, the chief financial officer owned 244,883 shares in the company, valued at $28,151,749.68. This represents a 23.95% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Bvf Partners L. P/Il sold 1,578,800 shares of the stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $106.50, for a total value of $168,142,200.00. Following the transaction, the director directly owned 240,123 shares in the company, valued at approximately $25,573,099.50. This represents a 86.80% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 3,080,096 shares of company stock valued at $337,948,342 over the last ninety days. 15.98% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Kymera Therapeutics

A number of hedge funds have recently added to or reduced their stakes in KYMR. GAMMA Investing LLC increased its stake in Kymera Therapeutics by 27.5% in the 2nd quarter. GAMMA Investing LLC now owns 454 shares of the company’s stock worth $52,000 after purchasing an additional 98 shares in the last quarter. Proficio Capital Partners LLC lifted its stake in Kymera Therapeutics by 1.8% during the second quarter. Proficio Capital Partners LLC now owns 11,045 shares of the company’s stock valued at $1,267,000 after buying an additional 200 shares in the last quarter. Glenmede Trust Co. NA lifted its stake in Kymera Therapeutics by 3.6% during the first quarter. Glenmede Trust Co. NA now owns 6,779 shares of the company’s stock valued at $565,000 after buying an additional 235 shares in the last quarter. Cetera Investment Advisers boosted its holdings in shares of Kymera Therapeutics by 7.5% in the first quarter. Cetera Investment Advisers now owns 3,602 shares of the company’s stock worth $300,000 after buying an additional 252 shares during the period. Finally, Larson Financial Group LLC increased its position in shares of Kymera Therapeutics by 36.9% in the fourth quarter. Larson Financial Group LLC now owns 1,064 shares of the company’s stock worth $83,000 after acquiring an additional 287 shares in the last quarter.

Kymera Therapeutics Stock Performance

Shares of NASDAQ KYMR opened at $117.67 on Tuesday. Kymera Therapeutics has a 1 year low of $47.90 and a 1 year high of $130.05. The stock’s 50-day simple moving average is $114.50 and its 200-day simple moving average is $97.12. The firm has a market cap of $9.78 billion, a price-to-earnings ratio of -36.32 and a beta of 1.96.

Kymera Therapeutics (NASDAQ:KYMR – Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($0.62) EPS for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.09. Kymera Therapeutics had a negative return on equity of 21.22% and a negative net margin of 285.33%.The firm had revenue of $65.00 million during the quarter, compared to the consensus estimate of $32.78 million. During the same quarter in the prior year, the business posted ($0.95) earnings per share. Kymera Therapeutics’s revenue for the quarter was up 465.2% on a year-over-year basis. As a group, research analysts predict that Kymera Therapeutics will post -3.83 EPS for the current year.

Kymera Therapeutics Company Profile

(Get Free Report)

Kymera Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines that selectively remove disease-causing proteins from cells. The company’s approach is based on targeted protein degradation, which uses small-molecule degraders to direct unwanted proteins to the cell’s natural disposal system rather than simply blocking their activity.

Kymera’s research and development activities are supported by its proprietary Pegasus platform, which is designed to identify degradable proteins and create drug candidates against them.

Recommended Stories